Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
Methods for the treatment of bacterial infections
US9593095B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593095-B2 |
| Application number | US-201414305649-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 16, 2014 |
| Priority date | Jun 14, 2013 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting K1 or K5 capsule biogenesis in a gram-negative bacterium which comprises administering to the bacterium an effective amount of a composition comprising an N-pyridin-4-yl-1,3-benzothiazole-6-carboxamide, a substituted pyridinyl derivative of N-pyridin-4-yl-1,3-benzothiazole-6-carboxamide, or a salt thereof. 2. The method of claim 1 , wherein the gram-negative bacteria is Campylobacter jejuni, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila , Methicillin-resistant Staphylococcus aureus (MRSA), Neisseria meningitides, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhimurium, Serratia marcescens, Staphylococcus aureus or a combination thereof.
Assignees
Inventors
Classifications
linked by a chain containing hetero atoms as chain links · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems · CPC title
- C07D333/24Primary
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9593095B2 cover?
- This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
- Who is the assignee on this patent?
- Univ Duke, Univ Kansas, Southern Res Inst, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D333/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).